CL2008001509A1 - Composicion farmaceutica de liberacion prolongada que comprende micro-particulas con una matriz que comprende un polimero polilactido-co-glicolido lineal y uno ramificado y pamoato de pasireotida; proceso de elaboracion; micro-particulas; kit; uso para tratar una enfermedad asociada con un exceso de secrecion de gh y/o igf-1. - Google Patents
Composicion farmaceutica de liberacion prolongada que comprende micro-particulas con una matriz que comprende un polimero polilactido-co-glicolido lineal y uno ramificado y pamoato de pasireotida; proceso de elaboracion; micro-particulas; kit; uso para tratar una enfermedad asociada con un exceso de secrecion de gh y/o igf-1.Info
- Publication number
- CL2008001509A1 CL2008001509A1 CL2008001509A CL2008001509A CL2008001509A1 CL 2008001509 A1 CL2008001509 A1 CL 2008001509A1 CL 2008001509 A CL2008001509 A CL 2008001509A CL 2008001509 A CL2008001509 A CL 2008001509A CL 2008001509 A1 CL2008001509 A1 CL 2008001509A1
- Authority
- CL
- Chile
- Prior art keywords
- igf
- microparticles
- kit
- micro
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
Abstract
Composición farmacéutica para liberación prolongada que comprende micro-partículas con una matriz polimérica que comprende uno o más polímeros biodegradables y pamoato de pasireotida; proceso de elaboración; micro-partículas; kit; y uso en el tratamiento de una enfermedad asociada a un exceso de secreción de gh y/o igf-1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07108796 | 2007-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008001509A1 true CL2008001509A1 (es) | 2009-05-08 |
Family
ID=38222465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2008001509A CL2008001509A1 (es) | 2007-05-24 | 2008-05-23 | Composicion farmaceutica de liberacion prolongada que comprende micro-particulas con una matriz que comprende un polimero polilactido-co-glicolido lineal y uno ramificado y pamoato de pasireotida; proceso de elaboracion; micro-particulas; kit; uso para tratar una enfermedad asociada con un exceso de secrecion de gh y/o igf-1. |
Country Status (42)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR057181A1 (es) * | 2005-11-30 | 2007-11-21 | Astra Ab | Nueva forma de dosificacion de combinacion |
| WO2012083026A1 (en) * | 2010-12-15 | 2012-06-21 | Evonik Degussa Corporation | Branched polyol polyesters, blends and pharmaceutical formulations comprising same |
| HUE046004T2 (hu) | 2011-04-25 | 2020-01-28 | Shan Dong Luye Pharm Co Ltd | Risperidon nyújtott hatóanyagleadású mikroszféra készítmény |
| TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| ES2834318T3 (es) * | 2012-05-25 | 2021-06-17 | Camurus Ab | Formulaciones de agonistas de receptores de la somatostatina |
| US10821200B2 (en) | 2016-12-05 | 2020-11-03 | Hyalo Technologies, LLC | Method of sterilization of microparticles |
| EP3339372A1 (en) * | 2016-12-22 | 2018-06-27 | Solvay SA | Glycolic acid polymer composition |
| CN110870853B (zh) * | 2018-08-29 | 2020-12-11 | 深圳翰宇药业股份有限公司 | 缓释帕瑞肽微球及其制备方法 |
| MX2021006601A (es) * | 2018-12-04 | 2021-07-07 | Vanda Pharmaceuticals Inc | Administracion de iloperidona de liberacion lenta. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| CA2316052C (en) * | 1989-07-07 | 2008-09-02 | David Bodmer | Sustained release formulations of water soluble peptides |
| FI106926B (fi) * | 1989-07-07 | 2001-05-15 | Novartis Ag | Menetelmä pitkäaikaisesti vapautuvan koostumuksen muodostamiseksi |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| IE960308A1 (en) * | 1996-04-23 | 1997-11-05 | Kinerton Ltd | Sustained release ionic conjugate |
| AU5678398A (en) * | 1997-01-29 | 1998-08-18 | Takeda Chemical Industries Ltd. | Sustained-release microspheres, their production and use |
| EP1240896A3 (en) | 1998-07-23 | 2003-03-26 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Encapsulation of water soluble peptides |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| GB0326602D0 (en) * | 2003-11-14 | 2003-12-17 | Novartis Ag | Organic compounds |
| MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
| EP1689429A1 (en) * | 2003-11-25 | 2006-08-16 | Novartis AG | Biomarkers for the efficacy of somatostatin analogue treatment |
-
2008
- 2008-05-22 PE PE2008000880A patent/PE20090387A1/es not_active Application Discontinuation
- 2008-05-22 AR ARP080102168A patent/AR066677A1/es not_active Application Discontinuation
- 2008-05-23 JP JP2010508860A patent/JP5507447B2/ja active Active
- 2008-05-23 US US12/600,740 patent/US20100178344A1/en not_active Abandoned
- 2008-05-23 CN CN200880016626.4A patent/CN101677965B/zh active Active
- 2008-05-23 NZ NZ580589A patent/NZ580589A/en not_active IP Right Cessation
- 2008-05-23 TW TW097119228A patent/TWI412373B/zh not_active IP Right Cessation
- 2008-05-23 EA EA200901523A patent/EA018203B1/ru not_active IP Right Cessation
- 2008-05-23 KR KR1020097026865A patent/KR20100017904A/ko not_active Ceased
- 2008-05-23 BR BRPI0811904-0A2A patent/BRPI0811904A2/pt not_active IP Right Cessation
- 2008-05-23 SI SI200832103T patent/SI2164473T1/sl unknown
- 2008-05-23 EP EP08759948.6A patent/EP2164473B1/en active Active
- 2008-05-23 PL PL08759948T patent/PL2164473T3/pl unknown
- 2008-05-23 PA PA20088781501A patent/PA8781501A1/es unknown
- 2008-05-23 UA UAA200912088A patent/UA97396C2/ru unknown
- 2008-05-23 UY UY31103A patent/UY31103A1/es not_active Application Discontinuation
- 2008-05-23 EP EP19196299.2A patent/EP3666263A1/en not_active Withdrawn
- 2008-05-23 MY MYPI20094854A patent/MY148915A/en unknown
- 2008-05-23 ES ES08759948T patent/ES2761227T3/es active Active
- 2008-05-23 WO PCT/EP2008/056347 patent/WO2008142153A1/en active Application Filing
- 2008-05-23 KR KR1020157032784A patent/KR101930588B1/ko active Active
- 2008-05-23 MX MX2009012536A patent/MX2009012536A/es active IP Right Grant
- 2008-05-23 AU AU2008252931A patent/AU2008252931B2/en active Active
- 2008-05-23 ME MEP-2009-331A patent/ME00955B/me unknown
- 2008-05-23 CL CL2008001509A patent/CL2008001509A1/es unknown
- 2008-05-23 HU HUE08759948A patent/HUE046490T2/hu unknown
- 2008-05-23 GE GEAP200811569A patent/GEP20125582B/en unknown
- 2008-05-23 PT PT87599486T patent/PT2164473T/pt unknown
- 2008-05-23 DK DK08759948.6T patent/DK2164473T3/da active
- 2008-05-23 CA CA2683935A patent/CA2683935C/en active Active
-
2009
- 2009-10-14 ZA ZA200907168A patent/ZA200907168B/xx unknown
- 2009-10-15 IL IL201571A patent/IL201571B/en active IP Right Grant
- 2009-10-23 CR CR11078A patent/CR11078A/es unknown
- 2009-10-29 TN TNP2009000447A patent/TN2009000447A1/fr unknown
- 2009-11-20 NI NI200900207A patent/NI200900207A/es unknown
- 2009-11-20 DO DO2009000262A patent/DOP2009000262A/es unknown
- 2009-11-20 CU CU2009000200A patent/CU24028B1/es active IP Right Grant
- 2009-11-20 GT GT200900302A patent/GT200900302A/es unknown
- 2009-11-23 HN HN2009003296A patent/HN2009003296A/es unknown
- 2009-11-24 SV SV2009003421A patent/SV2009003421A/es unknown
- 2009-12-11 EC EC2009009793A patent/ECSP099793A/es unknown
- 2009-12-14 MA MA32419A patent/MA31445B1/fr unknown
- 2009-12-22 CO CO09146673A patent/CO6241097A2/es active IP Right Grant
- 2009-12-23 SM SM200900099T patent/SMP200900099B/it unknown
-
2013
- 2013-01-17 US US13/743,385 patent/US9351923B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008001509A1 (es) | Composicion farmaceutica de liberacion prolongada que comprende micro-particulas con una matriz que comprende un polimero polilactido-co-glicolido lineal y uno ramificado y pamoato de pasireotida; proceso de elaboracion; micro-particulas; kit; uso para tratar una enfermedad asociada con un exceso de secrecion de gh y/o igf-1. | |
| AR063621A1 (es) | Matriz polimerica insoluble en agua para la administracion de farmacos | |
| ES2649340T3 (es) | Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer | |
| ES2502472T3 (es) | Composición adhesiva para su uso en un inmunosensor | |
| CR11849A (es) | Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad | |
| GB2465677B (en) | Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes | |
| CL2008000893A1 (es) | Composición para el cuidado bucal que comprende una cantidad efectiva de un aminoácido básico y un agente antibacteriano; uso en el tratamiento antibacteriano de la cavidad bucal. | |
| CL2008002042A1 (es) | Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos. | |
| CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
| CL2009000202A1 (es) | Profármaco que comprende un péptido bioactivo de insulina o glucagón y un resto hidrofílico; derivado profarmacológico; composición farmacéutica que comprende dicho derivado; método para tratar diabetes. | |
| CL2011000501A1 (es) | Composición farmacéutica que comprende un agonista de gpr119 en combinación con un inhibidor de dpp-4 seleccionado de un grupo definido; uso para prevenir y/o tratar enfermedades metabólicas, como resistencia insulinica, diabetes, sindrome metabolico, obesidad, hiperlipidemia, osteoporosis, entre otras. | |
| CL2008003116A1 (es) | Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras. | |
| DE602006021237D1 (de) | Flammwidrige und lichtdiffundierende polycarbonatharzzusammensetzung und diese umfassende lichtdiffusionsplatte | |
| AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
| DK1610791T3 (da) | Implanterbar polymer anordning for vedvarende frigivelse af dopamin-agonist | |
| CL2008001038A1 (es) | Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano | |
| CL2012001080A1 (es) | Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida. | |
| CL2011003160A1 (es) | Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras. | |
| CL2009001077A1 (es) | Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo. | |
| BR112014017969A8 (pt) | Microesferas ou micropartículas bioerodíveis ou bio-degradáveis liberadas por tempo suspensas em uma formulação de droga injetável de formação de depósito | |
| CL2009001841A1 (es) | Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto. | |
| CL2007002371A1 (es) | Metodo para administrar un agente terapeutico que comprende administrar una composicion de nanoparticulas que comprende una matriz polimerica junto con un cation divalente que contiene un agente terapeutico; y dicha composicion. | |
| CL2008003489A1 (es) | Composicion de microcapsulas de copolimero lactico-co-glicolico (plga) o copolimero lactico co-glicolico y polietilenglicol (plga-peg) comprendiendo somatostatina o un analogo del mismo; y su uso para tratar y/o prevenir la diarrea. | |
| ATE510867T1 (de) | Herstellung von kammverzweigten polymeren | |
| CL2008002545A1 (es) | Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor. |